Summit Therapeutics Inc.

NasdaqGM:SMMT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 15.27 B

Share Price

USD 20.56

Avg Daily Volume

4,619,707

Change (1 day)

1.98%

Change (1 year)

163.59%

Change (YTD)

15.18%

Summit Therapeutics Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 5.85

Summit Therapeutics Inc. Current Ratio is 5.85 for the Trailing 12 Months (TTM) ending March 31, 2025, a 26.28% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.

Summit Therapeutics Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 4.63, a -63.60% change year over year.
Summit Therapeutics Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 12.73, a 181.66% change year over year.
Summit Therapeutics Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 4.52, a 103.52% change year over year.
Summit Therapeutics Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 2.22.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Current Ratio	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)

NasdaqGM: SMMT

Summit Therapeutics Inc.

CEO	Mr. Robert W. Duggan
IPO Date	March 5, 2015
Location	United States
Headquarters	One Broadway
Employees	159
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.